Literature DB >> 2813353

Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.

M A Butler1, M Iwasaki, F P Guengerich, F F Kadlubar.   

Abstract

Aromatic amines are well known as occupational carcinogens and are found in cooked foods, tobacco smoke, synthetic fuels, and agricultural chemicals. For the primary arylamines, metabolic N-oxidation by hepatic cytochromes P-450 is generally regarded as an initial activation step leading to carcinogenesis. The metabolic activation of 4-aminobiphenyl, 2-naphthylamine, and several heterocyclic amines has been shown recently to be catalyzed by rat cytochrome P-450ISF-G and by its human ortholog, cytochrome P-450PA. We now report that human hepatic microsomal caffeine 3-demethylation, the initial major step in caffeine biotransformation in humans, is selectively catalyzed by cytochrome P-450PA. Caffeine 3-demethylation was highly correlated with 4-aminobiphenyl N-oxidation (r = 0.99; P less than 0.0005) in hepatic microsomal preparations obtained from 22 human organ donors, and both activities were similarly decreased by the selective inhibitor, 7,8-benzoflavone. The rates of microsomal caffeine 3-demethylation, 4-aminobiphenyl N-oxidation, and phenacetin O-deethylation were also significantly correlated with each other and with the levels of immunoreactive human cytochrome P-450PA. Moreover, a rabbit polyclonal antibody raised to human cytochrome P-450PA was shown to inhibit strongly all three of these activities and to inhibit the N-oxidation of the carcinogen 2-naphthylamine and the heterocyclic amines, 2-amino-6-methyldipyrido-[1,2-a:3',2'-d]imidazole and 2-amino-3-methylimidazo[4,5-f]-quinoline. Human liver cytochrome P-450PA was also shown to catalyze caffeine 3-demethylation, 4-aminobiphenyl N-oxidation, and phenacetin O-deethylation. Thus, estimation of caffeine 3-demethylation activity in humans may be useful in the characterization of arylamine N-oxidation phenotypes and in the assessment of whether or not the hepatic levels of cytochrome P-450PA, as affected by environmental or genetic factors, contribute to interindividual differences in susceptibility to arylamine-induced cancers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2813353      PMCID: PMC298137          DOI: 10.1073/pnas.86.20.7696

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  The P450 gene superfamily: recommended nomenclature.

Authors:  D W Nebert; M Adesnik; M J Coon; R W Estabrook; F J Gonzalez; F P Guengerich; I C Gunsalus; E F Johnson; B Kemper; W Levin
Journal:  DNA       Date:  1987-02

2.  Carcinogenicity of mutagenic heterocyclic amines formed during the cooking process.

Authors:  T Sugimura
Journal:  Mutat Res       Date:  1985 Jun-Jul       Impact factor: 2.433

3.  Variability in caffeine metabolism.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

4.  Polymorphic metabolism of the carcinogen 2-acetylaminofluorene in human liver microsomes.

Authors:  R F Minchin; M E McManus; A R Boobis; D S Davies; S S Thorgeirsson
Journal:  Carcinogenesis       Date:  1985-12       Impact factor: 4.944

5.  Metabolic oxidation of carcinogenic arylamines by rat, dog, and human hepatic microsomes and by purified flavin-containing and cytochrome P-450 monooxygenases.

Authors:  G J Hammons; F P Guengerich; C C Weis; F A Beland; F F Kadlubar
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

6.  Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.

Authors:  L M Distlerath; P E Reilly; M V Martin; G G Davis; G R Wilkinson; F P Guengerich
Journal:  J Biol Chem       Date:  1985-07-25       Impact factor: 5.157

7.  Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat.

Authors:  S A Wrighton; C Campanile; P E Thomas; S L Maines; P B Watkins; G Parker; G Mendez-Picon; M Haniu; J E Shively; W Levin
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

8.  Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.

Authors:  L M Distlerath; F P Guengerich
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

9.  The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers.

Authors:  A N Kotake; D A Schoeller; G H Lambert; A L Baker; D D Schaffer; H Josephs
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

10.  Metabolic processing of 2-acetylaminofluorene by microsomes and six highly purified cytochrome P-450 forms from rabbit liver.

Authors:  M E McManus; R F Minchin; N Sanderson; D Schwartz; E F Johnson; S S Thorgeirsson
Journal:  Carcinogenesis       Date:  1984-12       Impact factor: 4.944

View more
  111 in total

1.  Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2.

Authors:  U Fuhr; B G Woodcock; M Siewert
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction.

Authors:  M C Cornelis; A El-Sohemy; H Campos
Journal:  J Med Genet       Date:  2004-10       Impact factor: 6.318

3.  Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.

Authors:  Sebastian Härtter; Anna Nordmark; Dirk-Matthias Rose; Leif Bertilsson; Gunnel Tybring; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

4.  Effect of caffeine on adenosine-induced reversible perfusion defects assessed by automated analysis.

Authors:  Joseph C Lee; John F Fraser; Adrian G Barnett; Leslie P Johnson; Melinda G Wilson; Catherine M McHenry; Darren L Walters; Christopher R Warnholtz; Frederick A Khafagi
Journal:  J Nucl Cardiol       Date:  2012-06       Impact factor: 5.952

Review 5.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

6.  Identification of carcinogen DNA adducts in human saliva by linear quadrupole ion trap/multistage tandem mass spectrometry.

Authors:  Erin E Bessette; Simon D Spivack; Angela K Goodenough; Tao Wang; Shailesh Pinto; Fred F Kadlubar; Robert J Turesky
Journal:  Chem Res Toxicol       Date:  2010-07-19       Impact factor: 3.739

7.  Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma.

Authors:  Yu-Jing Zhang
Journal:  World J Hepatol       Date:  2010-03-27

8.  Pre-pregnancy caffeine and caffeinated beverage intake and risk of spontaneous abortion.

Authors:  Audrey J Gaskins; Janet W Rich-Edwards; Paige L Williams; Thomas L Toth; Stacey A Missmer; Jorge E Chavarro
Journal:  Eur J Nutr       Date:  2016-08-29       Impact factor: 5.614

9.  Screening reactive metabolites bioactivated by multiple enzyme pathways using a multiplexed microfluidic system.

Authors:  Dhanuka P Wasalathanthri; Ronaldo C Faria; Spundana Malla; Amit A Joshi; John B Schenkman; James F Rusling
Journal:  Analyst       Date:  2012-10-25       Impact factor: 4.616

10.  Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.

Authors:  Christoph Sachse; Upinder Bhambra; Gillian Smith; Tracy J Lightfoot; Jennifer H Barrett; Jenna Scollay; R Colin Garner; Alan R Boobis; C Roland Wolf; Nigel J Gooderham
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.